{"success":true,"data":{"pressRelease":{"id":"2903","rtpr_id":"nPn9tzyb8a","ticker":"AQST","exchange":"NASDAQ","all_tickers":["AQST"],"title":"AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm","author":"PR Newswire","published_at":"2026-04-21T13:00:21.742Z","article_body":"AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm\n\nPR Newswire\n\nNEW YORK, April 21, 2026\n\nNEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the\nfollowing notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ:\nAQST).\n\n(https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.html)\n\nShareholders who purchased shares of AQST during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointment.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCONTACT US HERE:\nhttps://securitiesclasslaw.com/securities/aquestive-therapeutics-inc-loss-submission-form/?id=185676&from=4\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4668631-9&h=215910131&u=https%3A%2F%2Fsecuritiesclasslaw.com%2Fsecurities%2Faquestive-therapeutics-inc-loss-submission-form%2F%3Fid%3D185676%26from%3D4&a=https%3A%2F%2Fsecuritiesclasslaw.com%2Fsecurities%2Faquestive-therapeutics-inc-loss-submission-form%2F%3Fid%3D185676%26from%3D4)\n \n\nCLASS PERIOD: June 16, 2025 to January 8, 2026\n\nALLEGATIONS: According to the complaint, defendants provided investors with\npositive statements while, at the same time, disseminating materially false\nand misleading statements and/or concealing material adverse facts concerning\nthe true state of Aquestive's New Drug Application (NDA) for Anaphylm\n(Dibutepinephrine) sublingual film; pertinently, Aquestive concealed or\notherwise minimized the significance of the human factors involved in the use\nand deployment of its sublingual film, such as packaging, use, administration,\nand labeling.  On January 9, 2026, Aquestive announced that the Company was\nin receipt of a letter from the FDA identifying deficiencies that precluded\nlabeling discussions for Anaphylm. Moreover, Aquestive revealed that the\nletter from the FDA confirmed that the Agency's review of Anaphylm NDA was\nongoing and no final decision had been made, which effectively delayed the\napproval of Anaphylm well beyond the January 31, 2026 Prescription Drug User\nFee Act date.  Following this news, the price of Aquestive's common stock\ndeclined dramatically. From a closing market price of $6.21 per share on\nJanuary 8, 2026, Aquestive's stock price fell to $3.91 per share on January 9,\n2026, a decline of over 37% in a single day.\n\nDEADLINE: May 4, 2026 Shareholders should not delay in registering for this\nclass action. Register your information here:\nhttps://securitiesclasslaw.com/securities/aquestive-therapeutics-inc-loss-submission-form/?id=185676&from=4\n(https://securitiesclasslaw.com/securities/aquestive-therapeutics-inc-loss-submission-form/?id=185676&from=4)\n\nNEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased\nshares of AQST during the timeframe listed above, you will be enrolled in a\nportfolio monitoring software to provide you with status updates throughout\nthe lifecycle of the case. The deadline to seek to be a lead plaintiff is May\n4, 2026. There is no cost or obligation to you to participate in this case.\n\nWHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action\nlaw firm, and our mission is to protect the rights of all investors who have\nsuffered as a result of deceit, fraud, and illegal business practices. The\nGross Law Firm is committed to ensuring that companies adhere to responsible\nbusiness practices and engage in good corporate citizenship. The firm seeks\nrecovery on behalf of investors who incurred losses when false and/or\nmisleading statements or the omission of material information by a company\nlead to artificial inflation of the company's stock. Attorney advertising.\nPrior results do not guarantee similar outcomes.\n\nCONTACT:\nThe Gross Law Firm\n15 West 38th Street, 12th floor\nNew York, NY, 10018\nEmail: dg@securitiesclasslaw.com (mailto:dg@securitiesclasslaw.com)\nPhone: (646) 453-8903\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/aqst-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-aquestive-therapeutics-inc-securities-lawsuit--the-gross-law-firm-302748241.html\n(https://www.prnewswire.com/news-releases/aqst-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-aquestive-therapeutics-inc-securities-lawsuit--the-gross-law-firm-302748241.html)\n\nSOURCE The Gross Law Firm\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9tzyb8a","title":"AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm","author":"PR Newswire","ticker":"AQST","created":"2026-04-21T13:00:21.742Z","tickers":["AQST"],"exchange":"NASDAQ","article_body":"AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm\n\nPR Newswire\n\nNEW YORK, April 21, 2026\n\nNEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the\nfollowing notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ:\nAQST).\n\n(https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.html)\n\nShareholders who purchased shares of AQST during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointment.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCONTACT US HERE:\nhttps://securitiesclasslaw.com/securities/aquestive-therapeutics-inc-loss-submission-form/?id=185676&from=4\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4668631-9&h=215910131&u=https%3A%2F%2Fsecuritiesclasslaw.com%2Fsecurities%2Faquestive-therapeutics-inc-loss-submission-form%2F%3Fid%3D185676%26from%3D4&a=https%3A%2F%2Fsecuritiesclasslaw.com%2Fsecurities%2Faquestive-therapeutics-inc-loss-submission-form%2F%3Fid%3D185676%26from%3D4)\n \n\nCLASS PERIOD: June 16, 2025 to January 8, 2026\n\nALLEGATIONS: According to the complaint, defendants provided investors with\npositive statements while, at the same time, disseminating materially false\nand misleading statements and/or concealing material adverse facts concerning\nthe true state of Aquestive's New Drug Application (NDA) for Anaphylm\n(Dibutepinephrine) sublingual film; pertinently, Aquestive concealed or\notherwise minimized the significance of the human factors involved in the use\nand deployment of its sublingual film, such as packaging, use, administration,\nand labeling.  On January 9, 2026, Aquestive announced that the Company was\nin receipt of a letter from the FDA identifying deficiencies that precluded\nlabeling discussions for Anaphylm. Moreover, Aquestive revealed that the\nletter from the FDA confirmed that the Agency's review of Anaphylm NDA was\nongoing and no final decision had been made, which effectively delayed the\napproval of Anaphylm well beyond the January 31, 2026 Prescription Drug User\nFee Act date.  Following this news, the price of Aquestive's common stock\ndeclined dramatically. From a closing market price of $6.21 per share on\nJanuary 8, 2026, Aquestive's stock price fell to $3.91 per share on January 9,\n2026, a decline of over 37% in a single day.\n\nDEADLINE: May 4, 2026 Shareholders should not delay in registering for this\nclass action. Register your information here:\nhttps://securitiesclasslaw.com/securities/aquestive-therapeutics-inc-loss-submission-form/?id=185676&from=4\n(https://securitiesclasslaw.com/securities/aquestive-therapeutics-inc-loss-submission-form/?id=185676&from=4)\n\nNEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased\nshares of AQST during the timeframe listed above, you will be enrolled in a\nportfolio monitoring software to provide you with status updates throughout\nthe lifecycle of the case. The deadline to seek to be a lead plaintiff is May\n4, 2026. There is no cost or obligation to you to participate in this case.\n\nWHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action\nlaw firm, and our mission is to protect the rights of all investors who have\nsuffered as a result of deceit, fraud, and illegal business practices. The\nGross Law Firm is committed to ensuring that companies adhere to responsible\nbusiness practices and engage in good corporate citizenship. The firm seeks\nrecovery on behalf of investors who incurred losses when false and/or\nmisleading statements or the omission of material information by a company\nlead to artificial inflation of the company's stock. Attorney advertising.\nPrior results do not guarantee similar outcomes.\n\nCONTACT:\nThe Gross Law Firm\n15 West 38th Street, 12th floor\nNew York, NY, 10018\nEmail: dg@securitiesclasslaw.com (mailto:dg@securitiesclasslaw.com)\nPhone: (646) 453-8903\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/aqst-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-aquestive-therapeutics-inc-securities-lawsuit--the-gross-law-firm-302748241.html\n(https://www.prnewswire.com/news-releases/aqst-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-aquestive-therapeutics-inc-securities-lawsuit--the-gross-law-firm-302748241.html)\n\nSOURCE The Gross Law Firm\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-04-21T13:00:21.844710445Z","server_sent_at_ms":1776776421844},"received_at":"2026-04-21T13:00:21.901Z","source_url":"https://www.prnewswire.com/news-releases/aqst-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-aquestive-therapeutics-inc-securities-lawsuit--the-gross-law-firm-302748241.html"},"analysis":{"id":"1875","press_release_id":"2903","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["class action lawsuit alleging securities fraud","37% single-day stock decline cited in complaint","allegations of concealing material adverse facts regarding lead drug NDA"],"eventType":"legal_litigation","narrative":"The Gross Law Firm announced a class action lawsuit against Aquestive Therapeutics on behalf of investors who purchased shares between June 16, 2025, and January 8, 2026.\n\nThe complaint alleges the company made false or misleading statements regarding the New Drug Application for Anaphylm, specifically concealing issues related to human factors, packaging, and labeling.\n\nThe lawsuit follows a 37% stock decline on January 9, 2026, after the FDA identified deficiencies that effectively delayed the drug's approval beyond the PDUFA date.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Securities fraud class action filed over alleged misstatements regarding Anaphylm's FDA approval path."},"keyFigures":{"customDimensions":{"class_period_end":"January 8, 2026","share_price_jan_8":"$6.21","share_price_jan_9":"$3.91","class_period_start":"June 16, 2025","stock_decline_percent":"37%","lead_plaintiff_deadline":"May 4, 2026"}},"quotedText":"defendants provided investors with positive statements while, at the same time, disseminating materially false and misleading statements","namedEntities":{"people":[],"products":["Anaphylm","Dibutepinephrine"],"companies":[{"name":"Aquestive Therapeutics, Inc.","ticker":"AQST","relationship":"defendant"},{"name":"The Gross Law Firm","relationship":"plaintiff counsel"},{"name":"U.S. Food and Drug Administration","relationship":"regulatory body"}],"dollarAmounts":[{"amount":"$6.21","context":"closing market price on January 8, 2026"},{"amount":"$3.91","context":"stock price on January 9, 2026"}]},"materialImpact":{"score":4,"reasoning":"A class action lawsuit alleging securities fraud has been filed against the company. The suit references a specific prior event (FDA regulatory setback) that caused a 37% single-day stock drop, indicating high materiality and potential financial liability."},"tickerRelevance":{"others":[],"primary":"AQST"},"eventTypeSecondary":[]},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"bearish","material_impact_score":4,"narrative":"The Gross Law Firm announced a class action lawsuit against Aquestive Therapeutics on behalf of investors who purchased shares between June 16, 2025, and January 8, 2026.\n\nThe complaint alleges the company made false or misleading statements regarding the New Drug Application for Anaphylm, specifically concealing issues related to human factors, packaging, and labeling.\n\nThe lawsuit follows a 37% stock decline on January 9, 2026, after the FDA identified deficiencies that effectively delayed the drug's approval beyond the PDUFA date.","key_figures":{"customDimensions":{"class_period_end":"January 8, 2026","share_price_jan_8":"$6.21","share_price_jan_9":"$3.91","class_period_start":"June 16, 2025","stock_decline_percent":"37%","lead_plaintiff_deadline":"May 4, 2026"}},"named_entities":{"people":[],"products":["Anaphylm","Dibutepinephrine"],"companies":[{"name":"Aquestive Therapeutics, Inc.","ticker":"AQST","relationship":"defendant"},{"name":"The Gross Law Firm","relationship":"plaintiff counsel"},{"name":"U.S. Food and Drug Administration","relationship":"regulatory body"}],"dollarAmounts":[{"amount":"$6.21","context":"closing market price on January 8, 2026"},{"amount":"$3.91","context":"stock price on January 9, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-21T18:16:02.930Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:53.440Z"}},"durationMs":35993,"modelName":"glm-4.7"}}